GlassScriptPhysician profile
Jessica Hedeman
NPI 1639310196
$167,047.48
in general payments reported to CMS, 2019-2025
19 companies · $61K in 2025
The $61K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $7,054 · 2021: $6,491 · 2022: $8,949 · 2023: $52K · 2024: $21K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Travel and Lodging: $23K · Honoraria: $16K · Consulting Fee: $14K · Food and Beverage: $2,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,312.00 |
| Travel and Lodging | $22,912.29 |
| Honoraria | $16,110.00 |
| Consulting Fee | $14,310.00 |
| Food and Beverage | $2,606.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $99,555.59 | 2022-2025 | Gocovri, Gocovri |
| Neurocrine Biosciences, INC. | $43,057.48 | 2019-2025 | Ingrezza |
| Acorda Therapeutics, INC | $16,074.27 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $7,133.14 | 2019-2021 | |
| Boston Scientific Corporation | $336.73 | 2019-2025 | General - Dbs |
| Kyowa Kirin, INC. | $163.79 | 2020-2021 | |
| Abbvie INC. | $141.12 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $121.43 | 2023-2025 | Austedo Xr, Austedo Xr |
| Abbott Laboratories | $91.98 | 2019-2024 | Infinity |
| Acadia Pharmaceuticals INC | $79.30 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $64.11 | 2020-2021 | |
| Avion Pharmaceuticals | $50.04 | 2022 | |
| Medtronic, INC. | $37.08 | 2023 | Activa PC |
| Supernus Pharmaceuticals, INC. | $33.28 | 2025 | |
| Medtronic USA, INC. | $32.02 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $21.78 | 2023 | |
| Amneal Pharmaceuticals LLC | $20.79 | 2019 | |
| Revance Therapeutics, INC. | $16.89 | 2025 | Daxxify |
| Vertical Pharmaceuticals, LLC | $16.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Hedeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.